Northland Securities reissued their hold rating on shares of Intersect ENT, Inc. (NASDAQ:XENT) in a research report released on Friday. The brokerage currently has a $25.00 price target on the medical equipment provider’s stock.

A number of other equities analysts also recently issued reports on the company. Bank of America Corporation increased their price target on Intersect ENT from $33.00 to $40.00 and gave the stock a buy rating in a research report on Monday, September 11th. Zacks Investment Research raised Intersect ENT from a sell rating to a hold rating in a research report on Wednesday, July 26th. Canaccord Genuity raised their price objective on Intersect ENT from $32.00 to $37.00 and gave the company a buy rating in a research report on Wednesday, September 13th. BidaskClub downgraded Intersect ENT from a strong-buy rating to a buy rating in a research report on Tuesday, July 25th. Finally, Deutsche Bank AG set a $31.00 price objective on Intersect ENT and gave the company a buy rating in a research report on Wednesday, August 2nd. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $30.88.

Intersect ENT (NASDAQ XENT) opened at $28.50 on Friday.

Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.05. Intersect ENT had a negative return on equity of 16.02% and a negative net margin of 19.81%. The business had revenue of $22.31 million for the quarter, compared to the consensus estimate of $21.53 million. During the same quarter in the prior year, the company earned ($0.22) EPS. The business’s revenue was up 20.8% compared to the same quarter last year. analysts anticipate that Intersect ENT will post -0.61 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Intersect ENT, Inc. (XENT) Given “Hold” Rating at Northland Securities” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.watchlistnews.com/intersect-ent-inc-xent-given-hold-rating-at-northland-securities/1684621.html.

In other Intersect ENT news, CFO Jeryl L. Hilleman sold 12,833 shares of the stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $31.05, for a total value of $398,464.65. Following the completion of the sale, the chief financial officer now directly owns 27,833 shares in the company, valued at $864,214.65. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Lisa D. Earnhardt sold 20,000 shares of the stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $30.79, for a total value of $615,800.00. Following the completion of the sale, the insider now owns 525,868 shares of the company’s stock, valued at $16,191,475.72. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 134,563 shares of company stock worth $3,999,247. 13.70% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in XENT. FMR LLC raised its stake in Intersect ENT by 247.7% in the second quarter. FMR LLC now owns 1,482,909 shares of the medical equipment provider’s stock valued at $41,447,000 after buying an additional 1,056,389 shares during the last quarter. Alliancebernstein L.P. raised its stake in Intersect ENT by 2,746.9% in the second quarter. Alliancebernstein L.P. now owns 931,505 shares of the medical equipment provider’s stock valued at $26,036,000 after buying an additional 898,785 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in Intersect ENT in the second quarter valued at about $9,384,000. EAM Investors LLC purchased a new stake in Intersect ENT in the second quarter valued at about $4,542,000. Finally, State Street Corp raised its stake in Intersect ENT by 33.6% in the second quarter. State Street Corp now owns 552,344 shares of the medical equipment provider’s stock valued at $15,437,000 after buying an additional 138,968 shares during the last quarter. Institutional investors own 83.08% of the company’s stock.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.